poisar

Stocks · News reference

BioLineRx Announces $3.75M Registered Direct Offering Of ADSs At $2.78 Each And Concurrent Private Placement Of Warrants For Up To 2M ADSs

Aug 28, 2026, 12:03 PMBenzinga Newsdesk

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BLRX
Source
benzinga
Observed
Aug 28, 2026, 12:03 PM
Checked
Aug 28, 2026, 12:03 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jul 20, 2026, 11:07 AMBenzinga Newsdesk

    BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October

    Presentation Details:Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell LinesPresentation #: 1435ePPresentation type: e-PosterLocation: e-Poster

    Read original at benzinga
    BLRX